Bempedoic acid

Drug Profile

Bempedoic acid

Alternative Names: ESP-55016; ETC-1002

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Esperion Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
  • Mechanism of Action ATP citrate (pro S) lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia
  • Phase II Dyslipidaemias; Hypertension

Most Recent Events

  • 02 Oct 2017 Esperion Therapeutics completes enrolment in the CLEAR Wisdom, CLEAR Serenity and CLEAR Tranquility trials for Hypercholesterolaemia in USA (NCT02991118) (NCT02988115) (NCT03001076)
  • 08 Aug 2017 Top-line safety and efficacy data from a phase II trial in Hypercholesterolemia released by Esperion Therapeutics
  • 08 Aug 2017 Esperion Therapeutics completes enrolment in a phase II trial for Hypercholesterolemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top